Autolus Reports Complete Hematologic Remission in First Four AL Amyloidosis Trial Patients
Autolus said the first four patients in its Phase 1 AL amyloidosis study achieved complete hematologic remission.
Related stories
Boba Mint Announces Cease Trade Order
Boba Mint says it will rebrand Heatcheck and restructure assets; it also announces a cease trade order.
L impact | EQUITY | Nov 04, 2026, 03:01 PM UTC
Moderna Says mRNA-2808 Shows Responses in 4 of 11 Patients
Moderna reported responses in 4 of 11 patients in a Phase 1/2 study of mRNA-2808 for multiple myeloma.
L impact | EQUITY | Nov 04, 2026, 02:56 PM UTC
LUD: trading halted on NYSE American — additional information requested (last $4.00)
NYSE American halted trading in LUD (additional information requested). Last price $4.00.
L impact | EQUITY | Nov 04, 2026, 02:56 PM UTC
Duolingo shares surge 26.2% on strong daily active-user growth
Duolingo shares rose 26.2%.
M impact | EQUITY | Nov 04, 2026, 02:56 PM UTC
Electrolux Cuts Italian Jobs in New Plan, Announces Investment
M impact | EQUITY | Nov 04, 2026, 02:55 PM UTC
MoonLake Immunotherapeutics Shares Rise 0.8%
MoonLake Immunotherapeutics shares were up 0.8% following its Q3 financial results.
M impact | EQUITY | Nov 04, 2026, 02:54 PM UTC